I am very excited to join the
@huntsmancancer
as a post doctoral research fellow at the GU
#oncology
department. Looking forward to this exceptional opportunity.
👉Just in Biomedicines: high concordance between tissue and blood for BRCA mutations. Testing cfDNA➡️reliable information on BRCA mutational status➕viable alternative to solid tissue sequencing when unavailable
#ProstateCancer
Free access link
@OncoAlert
Just in 👉Our latest paper discusses
@PBarataMD
et al. crucial work assessing treatment intensification in Europe & the US, as well as treatment decisions in 1L mCRPC during the era of ADT intensification
@neerajaiims
@umangtalking
@vinay_onc
➡️
Happy to share our latest review on IO-based combinations in first-line Rx in mRCC
@tandfonline
@maughanonc
@neerajaiims
@sahuonc
Consistent ⬆️ outcomes with IO-based Rx with promising combinations underway 👉 biomarkers needed to optimize Rx selection
The
#ASCOdailynews
highlights SPOP mutation as a first biomarker for better response to ARPIs vs. docetaxel in de novo mCSPC. Further investigation of biomarkers is necessary to enhance the personalization of mCSPC treatment
@umangtalking
@nsayeghmd
@Huntsman_GU
Checkout Abs
#600
by Kosuke Takemura👉Impact of IO-based combination Rx on pts with brain mets ➡️ longer OS vs anti-VEGF monotherapy; Brain-directed local Rx (Surgery or SBRT) ➡️ longer OS
@IMDConline
@LuisMezaco
Just in
@NatureMedicine
👉Results from Ph3 TALAPRO-2 trial in 399 pts w/ HRR-deficient mCRPC
#prostatecancer
👉enza + tala vs. enza, rPFS HR 0.44, OS trending strongly HR 0.69, efficacy in multiple HRR gene subsets⬇️open access👉
@OncoAlert
@PCF_Science
We report in
@TheLancet
: Primary efficacy data from TALAPRO-2 Phase 3 trial in mCRPC
#prostatecancer
: Talazoparib + Enza improves outcomes in all subgroups vs Enza. Prospective tissue testing in 100% pts, randomization stratified by HRR status
@oncoalert
@urotoday
@PCF_Science
⭐️Just in
@TheLancet
#CONTACT03
by
@DrChoueiri
@montypal
: the combo cabo/atezo appears to be similar to cabo monoRx in pts who progressed on prior PD-1/L1 based combo w/⬆️rate of serious adv events➡️PD-L1 rechallenge in mRCC does not seem to be beneficial
1/ Results from
#CONTACT03
are out both
@ASCO
#ASCO23
and
@TheLancet
. The 1⃣st phase 3 trial to assess the efficacy of rechallenge with anti-PDL1 in ANY cancer type.
Kudos to
@montypal
, SC members,
@roche
, our patients, = for this phenomenal job.
Congrats
@neerajaiims
! Thank you for your dedication in making positive impact in education, advancing the cancer field, and most importantly empowering future leaders to thrive!
Comp Effect of 2L Cabo in mccRCC After 1L Ipi + Nivo vs. PD-1/L1i + TKI
#ESMO23
@urotoday
@ggebraelmd
@neerajaiims
@umangtalking
🚩n=237; 145 1L Ipi + Nivo vs 92 1L PD-1/L1i + TKI ➡️ Cabo
🚩TTNT w/ Cabo: 8 mos (95%CI 6.9-11) vs 7.5 mos (95%CI 6.3-16) HR 1.43, 95% CI 0.98–2.11
Pilot study to assess
#AI
as educational resource NOT decision maker, to assist patient NOT physician in
#oncology
➡️mostly accurate and not harmful➡️need for developed AI
#chatbot
based on evidence + intended for medical purposes